Efficacy of Recombinant Thrombomodulin for Poor Prognostic Cases of Acute Exacerbation in Idiopathic Interstitial Pneumonia: Secondary Analysis of the SETUP Trial

Overview

Journal BMJ Open Respir Res

Date 2020 May 20

PMID 32423894

Citations 2

Authors

Toru Arai

Hiroshi Kida

Yoshitaka Ogata

Satoshi Marumo

Hiroto Matsuoka

Iwao Gohma

Suguru Yamamoto

Masahide Mori

Chikatoshi Sugimoto

Kazunobu Tachibana

Masanori Akira

Yoshikazu Inoue

Affiliations

Soon will be listed here.

Abstract

Background: Acute exacerbation (AE) in idiopathic pulmonary fibrosis and other idiopathic interstitial pneumonias (IIPs) are poor prognostic events although they are usually treated with conventional therapy with corticosteroids and immunosuppressants. Previously, we demonstrated the safety and efficacy of recombinant human soluble thrombomodulin (rhTM) for AE-IIP in the SETUP trial. Here, we aimed to clarify the efficacy of rhTM for poor-prognosis cases of AE-IIP.

Methods: In this study, we included 85 patients, in whom fibrin degradation product (FDP)/d-dimer was evaluated at AE, from the 100 patients in the SETUP trial. The AE-IIP patients in the rhTM arm (n=39) were diagnosed using the Japanese criteria from 2014 to 2016 and treated with intravenous rhTM for 6 days in addition to the conventional therapy. The AE-IIP patients in the control arm (n=46) were treated with the conventional therapy without rhTM between 2011 and 2013. The subjects were classified into higher and lower FDP/d-dimer groups based on the Japanese Association for Acute Medicine Disseminated Intravascular Coagulation scoring system. A multivariate Cox proportional hazard regression analysis with stepwise selection was performed to reveal the prognostic factors of AE-IIP.

Results: We developed a prognostic scoring system using two significant prognostic factors, higher FDP/d-dimer at AE and prednisolone therapy before AE, with 3 and 2 points assigned for each parameter, respectively. The prognostic scores ranged from 0 to 5. Survival of AE-IIP patients with a prognostic score=0 was significantly better than that of patients with score ≥2. Survival was improved with the rhTM therapy (p<0.05) in the poor prognostic cases (score ≥2), but not in the good prognostic cases (score=0).

Conclusions: Treatment with rhTM might improve survival in AE-IIP cases with poor prognoses.UMIN000014969, date: 28 August 2014.

Citing Articles

Usefulness of Combined Measurement of Surfactant Protein D, Thrombin-Antithrombin III Complex, D-Dimer, and Plasmin-α2 Plasmin Inhibitor Complex in Acute Exacerbation of Interstitial Lung Disease: A Retrospective Cohort Study.

Takeshita Y, To M, Kurosawa Y, Furusho N, Kinouchi T, Tsushima K J Clin Med. 2024; 13(8).

PMID: 38673700 PMC: 11051190. DOI: 10.3390/jcm13082427.

Acute Exacerbation of Idiopathic Pulmonary Fibrosis With Concurrent Cardiac Amyloidosis: A Technetium Pyrophosphate Study.

Yanagihara T, Hatashima H, Ogata H, Moriuchi Y, Ishimatsu A, Otsuka J Cureus. 2024; 16(3):e56358.

PMID: 38633977 PMC: 11022005. DOI: 10.7759/cureus.56358.

References

Sato T, Teramukai S, Kondo H, Watanabe A, Ebina M, Kishi K . Impact and predictors of acute exacerbation of interstitial lung diseases after pulmonary resection for lung cancer. J Thorac Cardiovasc Surg. 2013; 147(5):1604-1611.e3. DOI: 10.1016/j.jtcvs.2013.09.050. View

Enomoto N, Suda T, Uto T, Kato M, Kaida Y, Ozawa Y . Possible therapeutic effect of direct haemoperfusion with a polymyxin B immobilized fibre column (PMX-DHP) on pulmonary oxygenation in acute exacerbations of interstitial pneumonia. Respirology. 2008; 13(3):452-60. DOI: 10.1111/j.1440-1843.2008.01290.x. View

Moll S, Lindley C, PESCATORE S, Morrison D, Tsuruta K, Mohri M . Phase I study of a novel recombinant human soluble thrombomodulin, ART-123. J Thromb Haemost. 2004; 2(10):1745-51. DOI: 10.1111/j.1538-7836.2004.00927.x. View

Horita N, Akahane M, Okada Y, Kobayashi Y, Arai T, Amano I . Tacrolimus and steroid treatment for acute exacerbation of idiopathic pulmonary fibrosis. Intern Med. 2011; 50(3):189-95. DOI: 10.2169/internalmedicine.50.4327. View

Gando S, Wada H, Asakura H, Iba T, Eguchi Y, Okamoto K . Evaluation of new Japanese diagnostic criteria for disseminated intravascular coagulation in critically ill patients. Clin Appl Thromb Hemost. 2005; 11(1):71-6. DOI: 10.1177/107602960501100108. View

Molyneaux P, Cox M, Wells A, Kim H, Ji W, Cookson W . Changes in the respiratory microbiome during acute exacerbations of idiopathic pulmonary fibrosis. Respir Res. 2017; 18(1):29. PMC: 5286769. DOI: 10.1186/s12931-017-0511-3. View

Cruz D, Perazella M, Bellomo R, De Cal M, Polanco N, Corradi V . Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic review. Crit Care. 2007; 11(2):R47. PMC: 2206475. DOI: 10.1186/cc5780. View

Collard H, Moore B, Flaherty K, Brown K, Kaner R, King Jr T . Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2007; 176(7):636-43. PMC: 2094133. DOI: 10.1164/rccm.200703-463PP. View

Arai T, Tachibana K, Sugimoto C, Inoue Y, Tokura S, Okuma T . High-dose prednisolone after intravenous methylprednisolone improves prognosis of acute exacerbation in idiopathic interstitial pneumonias. Respirology. 2017; 22(7):1363-1370. DOI: 10.1111/resp.13065. View

10.

Kataoka K, Taniguchi H, Kondoh Y, Nishiyama O, Kimura T, Matsuda T . Recombinant Human Thrombomodulin in Acute Exacerbation of Idiopathic Pulmonary Fibrosis. Chest. 2015; 148(2):436-443. DOI: 10.1378/chest.14-2746. View

11.

Raghu G, Collard H, Egan J, Martinez F, Behr J, Brown K . An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011; 183(6):788-824. PMC: 5450933. DOI: 10.1164/rccm.2009-040GL. View

12.

Tsushima K, Yamaguchi K, Kono Y, Yokoyama T, Kubo K, Matsumura T . Thrombomodulin for acute exacerbations of idiopathic pulmonary fibrosis: a proof of concept study. Pulm Pharmacol Ther. 2014; 29(2):233-40. DOI: 10.1016/j.pupt.2014.04.008. View

13.

Akira M, Hamada H, Sakatani M, Kobayashi C, Nishioka M, Yamamoto S . CT findings during phase of accelerated deterioration in patients with idiopathic pulmonary fibrosis. AJR Am J Roentgenol. 1997; 168(1):79-83. DOI: 10.2214/ajr.168.1.8976924. View

14.

Kolb M, Bondue B, Pesci A, Miyazaki Y, Song J, Bhatt N . Acute exacerbations of progressive-fibrosing interstitial lung diseases. Eur Respir Rev. 2018; 27(150). PMC: 9488799. DOI: 10.1183/16000617.0071-2018. View

15.

Tachibana K, Nishiyama A, Sugimoto C, Matsumuro A, Hirose M, Kitaichi M . Polymyxin-B hemoperfusion for acute exacerbation of idiopathic pulmonary fibrosis: serum IL-7 as a prognostic marker. Sarcoidosis Vasc Diffuse Lung Dis. 2011; 28(2):113-22. View

16.

Kondoh Y, Taniguchi H, Kawabata Y, Yokoi T, Suzuki K, Takagi K . Acute exacerbation in idiopathic pulmonary fibrosis. Analysis of clinical and pathologic findings in three cases. Chest. 1993; 103(6):1808-12. DOI: 10.1378/chest.103.6.1808. View

17.

Collard H, Ryerson C, Corte T, Jenkins G, Kondoh Y, Lederer D . Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. Am J Respir Crit Care Med. 2016; 194(3):265-75. DOI: 10.1164/rccm.201604-0801CI. View

18.

Okamoto T, Tanigami H, Suzuki K, Shimaoka M . Thrombomodulin: a bifunctional modulator of inflammation and coagulation in sepsis. Crit Care Res Pract. 2012; 2012:614545. PMC: 3299293. DOI: 10.1155/2012/614545. View

19.

Hayakawa S, Matsuzawa Y, Irie T, Rikitake H, Okada N, Suzuki Y . Efficacy of recombinant human soluble thrombomodulin for the treatment of acute exacerbation of idiopathic pulmonary fibrosis: a single arm, non-randomized prospective clinical trial. Multidiscip Respir Med. 2016; 11:38. PMC: 5098285. DOI: 10.1186/s40248-016-0074-z. View

20.

Akira M, Kozuka T, Yamamoto S, Sakatani M . Computed tomography findings in acute exacerbation of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2008; 178(4):372-8. DOI: 10.1164/rccm.200709-1365OC. View